Drug Search Results
More Filters [+]

ACAM-1000

Alternative Names: acam-1000, acam1000, acam 1000
Latest Update: 2014-01-22
Latest Update Note: Clinical Trial Update

Product Description

clonally derived, cell-culture manufactured vaccinia strain

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ACAM-1000

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Smallpox

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

H-300-002

P2

Terminated

Smallpox

2003-03-01

Recent News Events

Date

Type

Title